---
title: "FDA's ADC Guidance: What It Means for Bioanalysis, Immunogenicity, and Regulatory Submissions"
description: "FDA's 2024 clinical pharmacology guidance for ADCs: which analytes to measure from first-in-human, dosing, exposure-response, organ impairment, QTc, immunogenicity, and DDI."
image: https://www.crystalbiosolutions.com/hubfs/ADC%20structure.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Nov 22, 2026

# FDA's Clinical Pharmacology Guidance for ADCs: What to Plan From First-in-Human Onward

FDA's 2024 clinical pharmacology guidance for ADCs: which analytes to measure from first-in-human, dosing, exposure-response, organ impairment, QTc, immunogenicity, and DDI.

![FDA's ADC Guidance: What It Means for Bioanalysis, Immunogenicity, and Regulatory Submissions](https://www.crystalbiosolutions.com/hubfs/ADC%20structure.png)\\

In March 2024, FDA issued final guidance on clinical pharmacology considerations for antibody-drug conjugates (ADCs). It sets out FDA's current thinking on bioanalytical methods, dosing strategies, dose- and exposure-response analysis, intrinsic factors, QTc assessment, immunogenicity, and drug-drug interactions (DDIs). This summary highlights what each section asks of sponsors.

## Why ADCs need their own clinical pharmacology approach

An ADC is generally a small-molecule drug (the payload) conjugated by a chemical linker to an antibody or antibody fragment that recognizes an antigen on the target cell surface. Because the ADC is designed to deliver the payload directly to target tissue, systemic payload exposure can be relatively low compared with giving the payload alone orally or intravenously.

ADCs combine the selectivity of an antibody with the potency of a small molecule. The antibody and the payload have different pharmacokinetics (PK) and pharmacodynamics (PD), and each can independently affect safety and efficacy. Dosing strategy therefore has to account for both.

## Dosage selection

- FDA strongly encourages evaluating a broad dosage range.
- Consider both fixed and weight-based dosing where appropriate.
- Use exposure-response analyses from early studies to choose the dosing strategy for pivotal studies, including for specific patient subsets.
- Evaluate the effect of intrinsic and extrinsic factors on PK, safety, and efficacy to inform labeling and any risk mitigation for patient subsets.

## Bioanalytical approach

From first-in-human studies onward, the ADC and its constituent parts should be measured with validated assays. Dropping a constituent part from later studies should be justified by its PK in early trials, relevant nonclinical pharmacology, PK, and safety data, and preliminary exposure-response data on its contribution to safety or efficacy.

In practice, this usually means validated methods for conjugated antibody or ADC, total antibody, and unconjugated payload, with any active metabolites, from the start of clinical development.

## Dose- and exposure-response

Beyond the ADC's dose-response relationship, exposure-response analyses for safety and efficacy should be run for the ADC and its constituent parts. In later development, sponsors can justify not analyzing a particular constituent part. If the antibody target sheds into the circulation to a clinically meaningful extent, exposure-response should use the ADC and/or total antibody not bound to shed target.

## Intrinsic factors

Intrinsic factors that could change exposure to the ADC or its parts should be evaluated either in clinical studies through population PK analysis or in dedicated studies.

- **Organ impairment.** Renal or hepatic impairment can change unconjugated payload exposure and alter safety or efficacy. Dose modifications should consider PK, safety, and efficacy in the target population. If patients with organ impairment are enrolled in pivotal studies and their PK, safety, and efficacy data are available, a population PK approach can assess effects on unconjugated payload, active metabolites, and/or total antibody.
- **Pharmacogenomics.** Genotype evaluation may be recommended, depending on ADME information, systemic exposure of the unconjugated payload, and the antibody's role in the mechanism of action.

## QTc assessment

All ADC programs should submit a QT prolongation risk assessment and a QT assessment plan. The assessment should focus on the unconjugated payload, the linker, and any pharmacologically relevant metabolites, and QT risk should be characterized as for a small-molecule drug.

## Immunogenicity

ADCs generally have a narrow therapeutic range, so immunogenicity and its effect on PK, safety, and efficacy matter. A multi-tiered assessment should follow FDA's immunogenicity guidances and include a confirmatory assay that detects anti-drug antibodies (ADA) against the ADC.

## Drug-drug interactions

ADC programs should include an in vitro DDI risk assessment of the unconjugated payload and relevant constituent parts as inhibitor, inducer, and substrate, using both CYP enzyme and transporter assays. In vivo DDI characterization should follow FDA's DDI guidance; prospectively designed large clinical studies can also provide adequate characterization. In some cases, FDA may ask for an assessment of the antibody component's DDI potential.

## What this means for your program

The guidance makes the analyte strategy a day-one decision: what you measure in Phase 1 determines what exposure-response, organ impairment, QTc, and DDI questions you can answer later. Crystal Bio Solutions supports [PK assays for biologics and ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis), immunogenicity testing, and [clinical pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology) for ADC programs. [Contact us](https://www.crystalbiosolutions.com/contact-us) to plan your analyte strategy.

## Glossary

- **ADC:** antibody-drug conjugate
- **ADA:** anti-drug antibodies
- **DDI:** drug-drug interaction
- **MOA:** mechanism of action
- **PK / PD:** pharmacokinetics / pharmacodynamics

## Source

FDA. [Clinical Pharmacology Considerations for Antibody-Drug Conjugates: Guidance for Industry](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry). March 2024.

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team"
  },
  "dateModified" : "2026-11-22T17:58:51.774Z",
  "datePublished" : "2026-11-22T17:58:51.000Z",
  "headline" : "FDA's ADC Guidance: What It Means for Bioanalysis, Immunogenicity, and Regulatory Submissions",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/ADC%20structure.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/fda-guidance-on-clinical-pharmacology-considerations-for-adcs-key-points-for-sponsors",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```